News Column

Day Three of the 2014 BIO International Convention to Feature Former Secretary of State Hillary Rodham Clinton, Innovative Approaches for Transforming the Current Model for Developing New Treatments, and Approaches for Unlocking R&D Value

June 25, 2014

Day Two Highlighted Sir Richard Branson’s Journey through Forty Years of Business, the Connections between Biotech and National Security, and an Overview of How the Biotech Industry Drives Economic Development

SAN DIEGO--(BUSINESS WIRE)-- The 2014 BIO International Convention, the world’s largest biotechnology event, entered its third day today at the San Diego Convention Center. It will run through Thursday, June 26. Hosted by the Biotechnology Industry Organization, this year’s event is expected to attract more than 3,000 biotechnology companies and more than 15,000 attendees from 48 states and 65 countries.

Upcoming Convention Highlights Include:

  • Keynote Luncheon: Hillary Rodham Clinton, Former Secretary of State, Wednesday, June 25

    Media Coverage: The event is open to the press. All members of the media who attend the event must check in – and be provided credentials at Media Registration. Names and IDs will be checked. Seating for print media is NOT GUARANTEED. Once designated seating is full, media will be directed to an overflow room.

    Media entrance: Media may enter at the D/E entrances

    Live Truck Pre-Set: 8:00 AM PDT

    Broadcast Pre-Set: 9:30 AM PDT*Note the change in broadcast pre-set time

    Still Photography Pre-Set: 11:00 AM PDT

    IMPORTANT NOTE: Those bringing still cameras will be escorted to set location. All photographs will be captured within the first five minutes of the Keynote.
  • Super Session:EY 2014 Biotechnology Industry Report, Wednesday, June 25

    Ernst & Young’s 2014 biotechnology industry report explores approaches that allow companies to “unlock value” by conducting R&D in ways that are both more capital-efficient and better aligned with the need to demonstrate value. The report highlights three such approaches: precision medicine, adaptive trials and pre-commercial collaborations.
  • Super Session:AMP-lifying Innovation: NIH, Patient Organizations & Leading Biopharma Firms Mobilize to Tackle Tough Diseases, Wednesday, June 25

    The Accelerating Medicines Partnerships (AMP) is a new venture among the NIH, several non-profit organizations and 10 biopharmaceutical companies focused on transforming the current model for developing new treatments. The Session will highlight the goals and implementation plans for the new AMP program as well as explore the evolution of large-scale public private partnerships in an evolving innovation ecosystem.
  • Press Conference: BIO Ventures for Global Health to Announce New African Drug Development and Capacity Building Initiatives, Wednesday, June 25

    BIO Ventures for Global Health (BVGH), a nonprofit organization dedicated to building partnerships to help solve global health issues will announce two new, indigenous African drug development partnership programs at the 2014 BIO International, Convention, June 25 at 3:15pm in room 27A at the San Diego Convention Center. Speakers will also include Dr. Solomon Nwaka, Director and Head, of the African Network for Drugs and Diagnostics Innovation (ANDI) andDeputy Executive Secretary, Mr. Akinbode Samuel Agbaoyeof the National Universities Commission (NUC) of Nigeria along with Mr. Christopher J. Maiyaki, Chief of Staff to the Executive Secretary and CEO of NUC. The speakers will describe research partnership opportunities and objectives of Africa’s leading research institutions through BVGH partnering activities and programs.
  • Integrating Personalized Medicine into the Healthcare Equation, Wednesday, June 25

    The science driving personalized medicine continues to push innovation in medicine towards better patient (diagnosis, treatments, and cures). However, the regulatory, reimbursement, healthcare practice and research environments are not currently conducive to experiencing the full potential of personalized medicine. This panel will explore these challenges, and suggest policy solutions that are critical to the success of personalized medicine.
  • Patient-Focused Drug Development: Is the Promise Materializing?, Wednesday, June 25

    This session will discuss provisions in the 2012 FDA Safety and Innovation Act intended to facilitate patient involvement in drug development. These include an initiative to incorporate patient perspectives on disease severity and medical need into the review process; a FDASIA section to foster participation of patient representatives in appropriate FDA meetings with medical product sponsors and investigators and a new, more systematic and transparent framework to outline and communicate FDA benefit-risk approval decisions to the public.
  • Successful Industry-Disease Foundation Partnerships: A National Survey and Leadership Perspective, Wednesday, June 25

    Disease foundations are playing an increasingly important role in advancing research and helping to bring new treatments to market. Their unique expertise in specific disease areas can be invaluable to developing and disseminating new research tools, technologies and clinical protocols. In addition, these organizations have a keen understanding of patient needs, and access to clinical thought leaders and patients, which can enhance and accelerate the clinical development of new treatments. Industry and foundation executives share what they view as the key opportunities and challenges for industry-foundation collaborations.
  • Regulatory Transformation: As Alzheimer's Disease, Science, Research and Advocacy Move Toward Earlier Detection and Intervention, How Will Researchers Adapt to this Evolution?, Wednesday, June 25

    If realized, disease-modifying interventions targeted toward Alzheimer’s disease – treatments which actually slow or halt disease progression – would be a tremendous breakthrough for patients, family members and researchers. Research into disease-modifying interventions is increasingly targeted toward earlier stage patients. Although early intervention may offer the most promise for patients, this earlier focus creates challenges for researchers who have traditionally been asked to provide co-primary outcome measures which demonstrate both the cognitive as well as functional impacts of therapy. In order to identify the appropriate clinical trial endpoints – those which demonstrate clinical meaningfulness of treatment effects in the earlier stages of disease – a robust dialogue between researchers, regulators, patients, and caregivers must take place. In this session, a panel of notable researchers, informed advocates, and regulatory experts will present an overview of the current paradigm, discuss the anticipated challenges as research focuses earlier, and debate future requirements.
  • Are Vaccines Still Blockbuster Products?, Wednesday, June 25

    This session will look forward at the possible growth opportunities in the global vaccines market. The last ten years saw the launch of several multi-billion dollar vaccines such as the conjugated pneumonia and HPV vaccines. Were these vaccines just rare events in the market or are there other products that represent growth in global vaccines? Are new pediatric vaccines the only true blockbusters or does the future point to specialized vaccines against nosocomial infections, chronic diseases and cancer? Panelists will discuss the prospects for both global and niche vaccines and whether the projected growth of the vaccine market is possible.
  • Will Innovation Have a Place in the Evolving U.S. Healthcare Market?, Wednesday, June 25

    The term “value” is swiftly pushing the U.S. marketplace through system-wide changes, particularly since the passage of health reform. Most health care stakeholders are growing increasingly concerned that value is a euphemism for cost, rather than a healthy balance of cost, quality and patient outcomes, and fear it may eventually discourage future innovations. Launching new products in an environment where unit cost reigns over total cost of care and outcomes will be challenging. In other parts of the world, assessing a product’s value is well-established and is part of the decision-making process. Learn how biopharmaceuticals, payers and providers will incorporate the drive for value in their U.S. organizations moving forward.

    Day Two Session Highlights Included:

  • Sir Richard Branson, Founder, Virgin Group

    In a special Keynote Luncheon, Sir Richard Branson brought attendees through his journey over 40 years in business.
  • The BIO/Battelle State Initiatives Report 2014: The Impact of the Biosciences in State Economic Vitality

    This year’s BIO/Battelle State Initiatives Report describes the size, scope and performance of the bioscience industry sector at the national, state and metro level and reports on trends in state bioscience industry development efforts. A panel of state Governors examined in detail a series of key performance metrics and discussed state policies and programs designed to accelerate the growth of the biosciences. The discussion panel provided an analysis on where the industry stands today and how states can continue fostering a bioscience economy in challenging economic times.
  • Integrate and Collaborate to Drive Advancements in Oncology Treatments

    BioCentury Editor Susan Schaeffer led a Super Session in which panelists discussed the pressing need for companies to increase collaboration with each other and with industry stakeholders, including patient advocacy groups and academic medical centers, to speed the development and delivery of new medicines.

    Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.

    Media registration is open from 7:00am6:30pm at the San Diego Convention Center. The Convention program features more than 160 sessions in 8 breakout sessions and 9 specialty forums. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.

    The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.

    The Convention also features the BIO Business Forum, which has grown over the past thirteen years to become the industry's largest partnering event. This year’s Convention is set to break all previous partnering records, with over 28,000 meetings expected to take place. Powered by BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the opportunity for companies to initiate business contacts in a friendly environment and schedule private meetings prior to the Convention.

    Upcoming BIO Events

    BIO Latin America Conference

    September 9-11, 2014

    Rio de Janeiro, Brazil

    Livestock Biotech Summit

    September 16-18, 2014

    Sioux Falls, SD

    About BIO

    BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

    For more information:

    Visit http://www.bio.org

    Follow us on Twitter @IAmBiotech

    Join us on LinkedIn/MyBio

    Become a fan at facebook.com/IAmBiotech




    Biotechnology Industry Organization

    Abigail Hirsch, 202-962-9235

    Web: www.bio.org

    Blog: www.biotech-now.org

    Twitter: @IAmBiotech

    Source: Biotechnology Industry Organization


  • For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



    Source: Business Wire


    Story Tools






    HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters